Thursday, May 22, 2014
Publication and contact
Cells with reduced N-glycan variability for therapeutic
Cells with a modified Golgi
N-glycosylation pathway could be useful for producing proteins with improved
therapeutic properties. The GlycoDelete platform shortens the Golgi
N-glycosylation pathway in mammalian cells to decrease N-glycan variability
in proteins. In engineered human embryonic kidney (HEK) cells producing granulocyte
macrophage colony-stimulating factor (GM-CSF;
the protein had activity comparable to that of GM-CSF produced in the same
cell line without the GlycoDelete modifications. In GlycoDelete-engineered
HEK cells producing an anti-CD20
IgG, the antibody had a lower clearance rate than anti-CD20 IgG generated in
a cell line without the GlycoDelete modifications. Next steps could include
using the GlycoDelete platform to generate additional therapeutic proteins
and comparing their properties with the parent compound.
Published online May 22, 2014
Patent application filed;
licensing status unavailable
Meuris, L. et al. Nat.
Biotechnol.; published online April 20, 2014;
Contact: Nico Callewaert, Flanders Institute for
Biotechnology (VIB), Ghent, Belgium
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]